| Literature DB >> 24509477 |
Xiaofan Zhu1, Fuhong He2, Huimin Zeng1, Shaoping Ling2, Aili Chen3, Yaqin Wang4, Xiaomei Yan5, Wei Wei4, Yakun Pang4, Hui Cheng4, Chunlan Hua4, Yue Zhang6, Xuejing Yang7, Xin Lu7, Lihua Cao8, Lingtong Hao8, Lili Dong8, Wei Zou8, Jun Wu8, Xia Li7, Si Zheng7, Jin Yan8, Jing Zhou8, Lixia Zhang7, Shuangli Mi8, Xiaojuan Wang4, Li Zhang4, Yao Zou4, Yumei Chen4, Zhe Geng9, Jianmin Wang10, Jianfeng Zhou9, Xin Liu11, Jianxiang Wang4, Weiping Yuan4, Gang Huang5, Tao Cheng4, Qian-Fei Wang8.
Abstract
Acute leukemia characterized by chromosomal rearrangements requires additional molecular disruptions to develop into full-blown malignancy, yet the cooperative mechanisms remain elusive. Using whole-genome sequencing of a pair of monozygotic twins discordant for MLL (also called KMT2A) gene-rearranged leukemia, we identified a transforming MLL-NRIP3 fusion gene and biallelic mutations in SETD2 (encoding a histone H3K36 methyltransferase). Moreover, loss-of-function point mutations in SETD2 were recurrent (6.2%) in 241 patients with acute leukemia and were associated with multiple major chromosomal aberrations. We observed a global loss of H3K36 trimethylation (H3K36me3) in leukemic blasts with mutations in SETD2. In the presence of a genetic lesion, downregulation of SETD2 contributed to both initiation and progression during leukemia development by promoting the self-renewal potential of leukemia stem cells. Therefore, our study provides compelling evidence for SETD2 as a new tumor suppressor. Disruption of the SETD2-H3K36me3 pathway is a distinct epigenetic mechanism for leukemia development.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24509477 PMCID: PMC4440318 DOI: 10.1038/ng.2894
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330